Sandoz Launches Enzeevu Biosimilar In US For Retinal Diseases

By Reuters News

- SANDOZ GROUP AG SDZ.S:

  • SANDOZ LAUNCHES ENZEEVU IN THE US AND ANNOUNCES KEY PRIVATE LABEL AGREEMENT, EXPANDING TREATMENT CHOICE FOR PATIENTS WITH RETINAL DISEASES

  • TARGETS OVER 100 BIOSIMILARS IN PORTFOLIO BY 2040

  • ENZEEVU LAUNCH TARGETS US ANTI-VEGF MARKET ESTIMATED AT $9.60 BILLION

  • TO MANUFACTURE ENZEEVU FOR PRIVATE LABEL BEGINNING MID-2027

  • LAUNCHES ENZEEVU (AFLIBERCEPT-ABZV) 2 MG IN US

Further company coverage: SDZ.S

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk